Catalyst Wire Dossier Catalyst Wire Dossier

ISV-403 (0.6%)

ISV-403 · Bausch & Lomb Incorporated
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ISV-403 (0.6%), covering 2009-08-13 to 2009-08-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. [Phase 3]

See pricing